Clinical Trials Browser

Dehydration, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

NCT04209660 2025-10-07

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Phase 2 Active not recruiting

64 enrolled

Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT05010629 2025-05-31

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Phase 2 Active not recruiting

35 enrolled

Head & Neck

Carcinoma, Adenoid Cystic, Neoplasm Metastasis, Salivary Gland Neoplasms

NCT05694819 2025-05-22

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Phase 2 Active not recruiting

56 enrolled

Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT05074940 2025-04-10

Amivantamab in Adenoid Cystic Carcinoma

Phase 2 Active not recruiting

18 enrolled

Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Clinical Trials

iPRIME

APG-115 in Salivary Gland Cancer Trial

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Amivantamab in Adenoid Cystic Carcinoma